Retinoblastoma is a rare pediatric malignancy arising from the developing retina — current evidence favours the maturing cone precursor as the cell of origin — and is the paradigmatic example of the two-hit hypothesis of tumor suppressor gene inactivation. Biallelic loss of RB1 function initiates almost all retinoblastoma. In hereditary cases (40%), a germline RB1 mutation is inherited and a somatic second hit occurs, leading to bilateral/multifocal tumors and increased risk of secondary malignancies. In sporadic cases (60%), both RB1 alleles are inactivated somatically in a single retinal cell. Two qualifications matter mechanistically. First, biallelic RB1 loss is not strictly necessary: roughly 2-3% of unilateral tumors retain two functional RB1 alleles and are instead driven by high-level MYCN amplification. Second, RB1 loss alone is not sufficient in humans — progression to overt tumor requires additional events such as MYCN or MDM4 gain, BCOR mutation, and 1q/6p gain.
Ask a research question about Retinoblastoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Retinoblastoma
creation_date: '2026-01-26T02:55:13Z'
description: >-
Retinoblastoma is a rare pediatric malignancy arising from the developing
retina — current evidence favours the maturing cone precursor as the cell of
origin — and is the paradigmatic example of the two-hit hypothesis of tumor
suppressor gene inactivation. Biallelic loss of RB1 function initiates
almost all retinoblastoma. In hereditary cases (40%), a germline RB1
mutation is inherited and a somatic second hit occurs, leading to
bilateral/multifocal tumors and increased risk of secondary malignancies. In
sporadic cases (60%), both RB1 alleles are inactivated somatically in a
single retinal cell. Two qualifications matter mechanistically. First,
biallelic RB1 loss is not strictly necessary: roughly 2-3% of unilateral
tumors retain two functional RB1 alleles and are instead driven by
high-level MYCN amplification. Second, RB1 loss alone is not sufficient in
humans — progression to overt tumor requires additional events such as MYCN
or MDM4 gain, BCOR mutation, and 1q/6p gain.
categories:
- Pediatric Cancer
- Ocular Malignancy
- Hereditary Cancer Syndrome
parents:
- retinal cancer
has_subtypes:
- name: Hereditary Retinoblastoma
description: >-
Caused by germline RB1 mutation (first hit) present in all cells, with somatic
loss of the remaining allele in retinal cells. Typically bilateral or multifocal.
Patients have 50% chance of passing mutation to offspring and increased lifetime
risk of secondary malignancies including osteosarcoma.
evidence:
- reference: PMID:5279523
reference_title: "Mutation and cancer: statistical study of retinoblastoma."
supports: SUPPORT
snippet: "In the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells."
explanation: Knudson's analysis established that hereditary retinoblastoma involves germline inheritance of the first mutation.
- reference: PMID:20301625
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Each child of an individual with heritable retinoblastoma (H1) has a 50% chance of inheriting the RB1 pathogenic variant."
explanation: >-
Source for the 50% transmission risk stated in this subtype's
description; Knudson (PMID:5279523) establishes germline-first-hit
inheritance but does not quantify it. The secondary-malignancy clause
of the same description is evidenced on the `Secondary Malignancies`
phenotype, which carries the Dimaras osteosarcoma figure.
- name: Sporadic Retinoblastoma
description: >-
Both RB1 alleles are inactivated by somatic mutations in a single retinal
precursor cell. Typically unilateral and unifocal. No increased risk of
secondary malignancies and no familial transmission unless mosaicism present.
evidence:
- reference: PMID:5279523
reference_title: "Mutation and cancer: statistical study of retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In the nonhereditary form, both mutations occur in somatic cells."
explanation: Knudson established that sporadic retinoblastoma requires two somatic mutations in the same cell.
- name: MYCN-Amplified RB1-Wildtype Retinoblastoma
display_name: MYCN-Amplified RB1+/+ Retinoblastoma
description: >-
A rare molecular subtype (roughly 2-3% of unilateral non-familial
retinoblastoma) that retains two functional RB1 alleles and expresses
functional RB1 protein, driven instead by high-level MYCN amplification
(28-121 copies). These tumors present at a strikingly early age (median
~4.5 months), show distinct aggressive histology, and carry fewer of the
secondary copy-number changes typical of RB1-null retinoblastoma. This
subtype is the principal exception to the otherwise obligatory two-hit RB1
model and has direct clinical consequence: RB1 germline testing is
uninformative, so MYCN status must be assessed to explain an
RB1-mutation-negative unilateral tumor.
evidence:
- reference: PMID:23498719
reference_title: "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "No RB1 mutations (RB1(+/+)) were reported in 29 (2·7%) of 1068 unilateral retinoblastoma tumours. 15 of the 29 RB1(+/+) tumours had high-level MYCN oncogene amplification (28-121 copies; RB1(+/+)MYCN(A)), whereas none of 93 RB1(-/-) primary tumours tested showed MYCN amplification (p<0·0001)."
explanation: >-
Establishes the frequency of RB1-wildtype retinoblastoma in a
1068-tumor series and the mutually exclusive relationship between MYCN
amplification and biallelic RB1 loss.
- reference: PMID:23498719
reference_title: "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Amplification of the MYCN oncogene might initiate retinoblastoma in the presence of non-mutated RB1 genes."
explanation: >-
States the central mechanistic claim — that MYCN amplification can
initiate retinoblastoma without RB1 inactivation — which is the
counterexample to strict two-hit necessity.
- reference: PMID:23498719
reference_title: "Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "RB1(+/+)MYCN(A) tumours expressed functional RB1 protein, had fewer overall genomic copy-number changes in genes characteristic of retinoblastoma than did RB1(-/-) tumours, and showed distinct aggressive histological features."
explanation: >-
Confirms retained functional RB1 protein and the distinct genomic and
histologic profile of this subtype.
pathophysiology:
- name: Germline RB1 First-Hit Inactivation
conforms_to: "germline_two_hit_tumor_predisposition#Constitutional First-Hit Tumor Suppressor Inactivation"
description: >-
In the 40% of cases that are hereditary, a loss-of-function RB1 allele at
13q14 is present constitutionally — inherited from a parent or arising de
novo during gametogenesis — and is therefore carried by every retinal cell
of the affected child. The allele is recessive at the cellular level, so a
heterozygous retinal precursor is functionally normal; what the germline hit
changes is that the whole developing retina now sits one event away from
biallelic loss. This node is the constitutional predisposition itself, kept
separate from the biallelic tumor state it makes probable.
role: trigger
biological_scale: MOLECULAR
gene:
preferred_term: RB1
modifier: DECREASED
term:
id: hgnc:9884
label: RB1
genetic_context:
gene:
preferred_term: RB1
term:
id: hgnc:9884
label: RB1
variant_origin: GERMLINE
allelic_hit_role: FIRST_HIT
allelic_events:
- PATHOGENIC_VARIANT
zygosity: HETEROZYGOUS
functional_impact_category: LOSS_OF_FUNCTION
description: >-
Constitutional heterozygous RB1 loss of function, present in every
nucleated cell of a carrier and transmitted to offspring with 50%
probability.
cell_types:
- preferred_term: retinal progenitor cell
term:
id: CL:0002672
label: retinal progenitor cell
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
evidence:
- reference: PMID:5279523
reference_title: "Mutation and cancer: statistical study of retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In the dominantly inherited form, one mutation is inherited via the
germinal cells and the second occurs in somatic cells.
explanation: >-
Knudson's derivation of the germline first hit from retinoblastoma
epidemiology, which is the claim this node makes.
- reference: PMID:2877398
reference_title: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mutations affecting this locus may be inherited from a parent, may arise
during gametogenesis or may occur somatically.
explanation: >-
Identifies the three origins of the RB1 lesion, establishing that the
constitutional first hit may be inherited or arise de novo in the germline
— both of which produce a heritable predisposition.
downstream:
- target: Somatic RB1 Second-Hit Inactivation
description: >-
With one allele already inactivated in every retinal cell, a single
somatic event at the same locus becomes the rate-limiting step to tumor
initiation.
- name: Somatic RB1 Second-Hit Inactivation
conforms_to: "germline_two_hit_tumor_predisposition#Somatic Second-Hit Inactivation of the Wild-Type Allele"
description: >-
A somatic event inactivates the remaining wild-type RB1 allele in a single
retinal cell. Comparison of constitutional with tumour genotypes in
retinoblastoma showed the mechanism to be chromosomal rather than a second
independent point mutation in most tumors: mitotic nondisjunction losing the
wild-type chromosome 13, or mitotic recombination replacing the wild-type
13q14 region with a copy of the mutant one. Deletion of all or part of the
locus is also frequent. In sporadic (non-hereditary) retinoblastoma the same
two events occur somatically in one cell, which is why the sporadic form is
typically unilateral and unifocal.
role: amplifier
biological_scale: MOLECULAR
genetic_context:
gene:
preferred_term: RB1
term:
id: hgnc:9884
label: RB1
variant_origin: SOMATIC
allelic_hit_role: SECOND_HIT
allelic_events:
- LOSS_OF_HETEROZYGOSITY
- DELETION
functional_impact_category: LOSS_OF_FUNCTION
description: >-
Acquired inactivation of the retained wild-type RB1 allele in a retinal
cell, predominantly by loss of heterozygosity at 13q14.
biological_processes:
- preferred_term: mitotic recombination
modifier: INCREASED
term:
id: GO:0006312
label: mitotic recombination
cell_types:
- preferred_term: retinal progenitor cell
term:
id: CL:0002672
label: retinal progenitor cell
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
evidence:
- reference: PMID:6633649
reference_title: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The homozygosity in these cases results from mitotic nondisjunction,
resulting in loss of the homologous wild-type chromosome, or from a
mitotic recombination event.
explanation: >-
Directly identifies the chromosomal mechanisms by which the second hit is
realized in retinoblastoma, which is what this node asserts.
- reference: PMID:2877398
reference_title: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The cDNA fragment detects a locus spanning at least 70 kilobases (kb) in
human chromosome band 13q14, all or part of which is frequently deleted in
retinoblastomas and osteosarcomas.
explanation: >-
Deletion of all or part of the RB1 locus in tumor tissue is the third
recognized route to second-hit inactivation alongside the two chromosomal
mechanisms.
downstream:
- target: RB1 Tumor Suppressor Inactivation
description: >-
Completion of the second hit leaves the retinal cell with no functional
RB1 allele, the biallelic state from which tumorigenesis proceeds.
- name: RB1 Tumor Suppressor Inactivation
conforms_to: "evading_growth_suppressors#Tumor Suppressor Inactivation"
description: >-
The RB1 gene encodes the retinoblastoma protein (pRB), a critical regulator of
the cell cycle. Biallelic RB1 loss removes the constraint on E2F transcription
factors, allowing uncontrolled progression through the G1/S checkpoint.
Retinoblastoma exemplifies Knudson's two-hit hypothesis: in hereditary cases,
one mutation is inherited and the second is somatic; in sporadic cases, both
mutations occur somatically in the same cell.
cell_types:
- preferred_term: retinal progenitor cell
term:
id: CL:0002672
label: retinal progenitor cell
biological_processes:
- preferred_term: G1/S transition of mitotic cell cycle
modifier: ABNORMAL
term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Loss of Cell Cycle Checkpoint Control
description: pRB loss releases E2F transcription factors from inhibition
- name: Loss of Cell Cycle Checkpoint Control
conforms_to: "evading_growth_suppressors#Loss of Cell-Cycle Checkpoint Control"
description: >-
pRB normally binds and inhibits E2F transcription factors during G1 phase.
When pRB is phosphorylated by cyclin-dependent kinases or functionally lost,
E2F is released to activate genes required for S-phase entry, including
cyclins, DNA replication factors, and proliferative genes.
biological_processes:
- preferred_term: cell cycle checkpoint signaling
modifier: DECREASED
term:
id: GO:0000075
label: cell cycle checkpoint signaling
- preferred_term: positive regulation of transcription by RNA polymerase II
modifier: INCREASED
term:
id: GO:0045944
label: positive regulation of transcription by RNA polymerase II
downstream:
- target: Uncontrolled Retinal Cell Proliferation
description: E2F-driven gene expression promotes S-phase entry and cell division
- name: Uncontrolled Retinal Cell Proliferation
conforms_to: "evading_growth_suppressors#Unrestrained Proliferation"
description: >-
Loss of pRB-mediated cell cycle control results in constitutive E2F activity,
driving retinal progenitor cells through repeated rounds of DNA replication
and cell division. This uncontrolled proliferation leads to tumor formation.
cell_types:
- preferred_term: retinal progenitor cell
term:
id: CL:0002672
label: retinal progenitor cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:5279523
reference_title: "Mutation and cancer: statistical study of retinoblastoma."
supports: SUPPORT
snippet: "retinoblastoma is a cancer caused by two mutational events. In the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells. In the nonhereditary form, both mutations occur in somatic cells."
explanation: This is the foundational Knudson paper establishing the two-hit hypothesis based on statistical analysis of retinoblastoma cases.
histopathology:
- name: Intraocular Malignancy
finding_term:
preferred_term: Retinoblastoma
term:
id: NCIT:C7541
label: Retinoblastoma
frequency: VERY_FREQUENT
description: >-
Retinoblastoma is the most common intraocular malignancy in children.
evidence:
- reference: PMID:41567907
reference_title: "Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Retinoblastoma is the most common intraocular malignancy in children."
explanation: Abstract states retinoblastoma is the most common intraocular malignancy in children; the pediatric restriction is part of the claim.
notes: >-
The pediatric restriction matters: retinoblastoma is not the most common
intraocular malignancy overall — in adults that is uveal melanoma. This
contrast is not covered by the cited PMID:41567907 snippet and is recorded
here as an uncited orienting note rather than as an evidenced claim.
phenotypes:
- category: Ocular
name: Leukocoria
frequency: VERY_FREQUENT
diagnostic: true
description: >-
White pupillary reflex (cat's eye reflex) is the most common presenting sign,
resulting from light reflecting off the tumor surface. Often noticed in
photographs or by parents.
phenotype_term:
preferred_term: Leukocoria
term:
id: HP:0000555
label: Leukocoria
evidence:
- reference: PMID:41567907
reference_title: "Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common presenting symptoms were leukocoria (93, 93%) and strabismus (40, 40%)."
explanation: >-
93% in a 101-patient enucleated high-risk subcohort (PMID:41567907); the
larger unselected series (PMID:9544909) attributes leukocoria as the
sole presenting sign in 56.2%. VERY_FREQUENT reflects the Dimaras
review's "most common sign" wording (Pattern C) rather than either
cohort figure, since both an unselected series and a high-risk
subcohort agree leukocoria is the single most common presenting sign.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common sign is leukocoria (white pupil)"
explanation: Dimaras et al. identify leukocoria as the most common presenting sign of retinoblastoma.
- category: Ocular
name: Strabismus
frequency: FREQUENT
diagnostic: true
description: >-
Misalignment of the eyes is the second most common presenting sign, occurring
when the tumor affects macular vision and disrupts binocular fusion.
phenotype_term:
preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
evidence:
- reference: PMID:41567907
reference_title: "Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common presenting symptoms were leukocoria (93, 93%) and strabismus (40, 40%)."
explanation: >-
40% in a 101-patient enucleated high-risk subcohort (PMID:41567907); the
larger unselected series (PMID:9544909) attributes strabismus as the
sole presenting sign in 23.6%. FREQUENT reflects the Dimaras review's
"second most common sign" wording (Pattern C) rather than either
cohort figure.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The second most common sign is strabismus (misaligned eyes) when central vision is lost."
explanation: Dimaras et al. identify strabismus as the second most common presenting sign, occurring when the tumor disrupts central vision.
- category: Ocular
name: Decreased Visual Acuity
frequency: FREQUENT
description: >-
Vision loss occurs when the tumor involves the macula or becomes large enough
to obstruct the visual axis.
phenotype_term:
preferred_term: Decreased visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
evidence:
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Location of tumour is the most important predictor of final visual acuity (near-normal visual acuity ≥0.5 in 22% of eyes with macular tumour, 67% of eyes with extrafoveal tumour)."
explanation: >-
Only 22% of eyes with macular-tumor involvement retain near-normal
visual acuity, i.e. most do not — consistent with the FREQUENT band for
reduced visual acuity as a disease-course outcome.
- reference: PMID:9544909
reference_title: "Presenting signs of retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the most common of which were leukocoria (56.2%), strabismus (23.6%), poor vision (7.7%), and family history (6.8%)"
explanation: >-
Reports "poor vision" as the sole presenting complaint leading to
diagnosis in 7.7% of a 1265-patient cohort — a presenting-complaint
rate (each patient assigned exactly one of thirty-two presenting
signs), not an overall phenotype-prevalence rate, so it does not
support a lower frequency band on its own. Retained for context
alongside the disease-course figure above.
- reference: PMID:31956625
reference_title: "Epidemiology and clinical features of retinoblastoma: A tertiary care center's experience in India."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vision loss was observed in 46.2%."
explanation: Quantifies vision loss as a common associated feature in a tertiary-care retinoblastoma cohort.
- category: Ocular
name: Ocular Pain
frequency: OCCASIONAL
description: >-
Eye pain may occur with advanced disease causing secondary glaucoma or
inflammation.
phenotype_term:
preferred_term: Eye pain
term:
id: HP:0200026
label: Ocular pain
evidence:
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Children presenting with orbital retinoblastoma are usually in severe pain and discomfort that may be alleviated with judicious use of anticancer therapy, including conventional chemotherapy, even when no curative intent is pursued."
explanation: >-
Confirms severe ocular/orbital pain as a feature of advanced (orbital)
retinoblastoma, supporting the disease-to-phenotype association in this
entry's description; the same review separately names secondary
neovascular glaucoma among the drivers of advanced/refractory disease.
Neither this review nor the Abramson/Suárez presenting-signs cohorts
(PMID:9544909, PMID:41567907) name ocular pain as a distinct
quantified presenting sign, so OCCASIONAL is a Pattern D clinical
estimate — advanced/orbital presentation is itself uncommon where
screening catches disease early — rather than a cohort-derived figure.
- category: Neurologic
name: Trilateral Retinoblastoma
frequency: VERY_RARE
description: >-
An intracranial midline embryonal tumor — most often pineoblastoma, less
often suprasellar or parasellar — arising in a child with bilateral or
familial retinoblastoma. It reflects the same germline RB1 lesion acting
in the pineal gland, which is embryologically photoreceptor-related, and
is therefore a synchronous or metachronous primary rather than a
metastasis. Its presence is itself diagnostic of germline disease
(GeneReviews H1 risk category) and it carries a poor prognosis, which is
why baseline and surveillance neuroimaging is recommended in germline
carriers. The pineal tumor is curated separately as `Pineoblastoma`.
phenotype_term:
preferred_term: Malignant neoplasm of the central nervous system
term:
id: HP:0100836
label: Malignant neoplasm of the central nervous system
evidence:
- reference: PMID:20301625
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "trilateral retinoblastoma (retinoblastoma with intracranial central nervous system midline embryonic tumor)"
explanation: >-
GeneReviews defines trilateral retinoblastoma as retinoblastoma with an
intracranial CNS midline embryonal tumor, and places it in the H1
category of individuals presumed to carry a germline RB1 variant.
- category: Systemic
name: Secondary Malignancies
frequency: OCCASIONAL
description: >-
Patients with hereditary retinoblastoma have significantly increased risk of
secondary cancers, particularly osteosarcoma, soft tissue sarcomas, and
melanoma. Risk is increased further by external beam radiation therapy.
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
evidence:
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Individuals with germline RB1 mutation who have been treated with radiotherapy have high risk to develop specific second cancers (50% risk to develop cancer at 50 years if they received external beam radiotherapy (EBRT)), including leiomyosarcoma, osteosarcoma, melanoma, lung and bladder cancer."
explanation: Quantifies the elevated second-cancer risk, including osteosarcoma, in germline RB1 carriers treated with external beam radiotherapy.
biochemical:
- name: RB1 Genetic Testing
notes: >-
Molecular testing identifies RB1 mutations including point mutations, small
insertions/deletions, large deletions, and promoter hypermethylation. Testing
is essential for genetic counseling and surveillance of family members.
genetic:
- name: RB1
gene_term:
preferred_term: RB1
term:
id: hgnc:9884
label: RB1
association: Germline and Somatic Mutations
evidence:
- reference: CGGV:assertion_f8c79621-7ace-4c0c-874e-a315a2e6c872-2020-07-30T213929.219Z
reference_title: "RB1 / retinoblastoma (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "RB1 | HGNC:9884 | retinoblastoma | MONDO:0008380 | AD | Definitive"
explanation: ClinGen classifies the RB1-retinoblastoma gene-disease relationship as definitive with autosomal dominant inheritance.
inheritance:
- name: Autosomal Dominant
notes: >-
RB1 (13q14.2) encodes the retinoblastoma protein, the first tumor suppressor
gene identified. Loss-of-function mutations include nonsense, frameshift, splice
site, and large deletions. Germline mutations are present in 40% of cases.
Hereditary retinoblastoma follows autosomal dominant inheritance with high
but incomplete penetrance (approximately 90%).
treatments:
- name: Focal Therapy (Laser/Cryotherapy)
description: >-
Small tumors may be treated with focal ablation including laser photocoagulation
or cryotherapy. These treatments spare vision and avoid systemic toxicity.
treatment_term:
preferred_term: laser ablation therapy
term:
id: NCIT:C111241
label: Laser Ablation
evidence:
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Focal therapy (laser therapy, cryotherapy, local chemotherapy) is the local application of therapy to the eye, under direct visualization through the pharmacologically dilated pupil."
explanation: >-
Confirms laser therapy and cryotherapy as focal-ablation modalities
applied directly to small tumors.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "primary treatments for intraocular disease include enucleation, intravenous chemotherapy (IVC) with focal therapy (laser therapy, cryotherapy), intra-arterial chemotherapy (IAC) with focal therapy, and focal therapy alone when tumours are small at diagnosis."
explanation: Lists focal therapy (laser/cryotherapy), alone or combined with chemotherapy, among the standard primary treatments for small intraocular retinoblastoma.
- name: Chemotherapy
description: >-
Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces
tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers
melphalan directly to the ophthalmic artery for localized effect.
treatment_term:
preferred_term: Chemotherapy
term:
id: NCIT:C15632
label: Chemotherapy
therapeutic_agent:
- preferred_term: carboplatin
term:
id: CHEBI:31355
label: carboplatin
- preferred_term: vincristine
term:
id: CHEBI:28445
label: vincristine
- preferred_term: etoposide
term:
id: CHEBI:4911
label: etoposide
- preferred_term: melphalan
term:
id: CHEBI:28876
label: melphalan
evidence:
- reference: PMID:41567907
reference_title: "Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "adjuvant chemotherapy using the VEC regimen (Vincristine, Etoposide, and Carboplatin)"
explanation: Confirms systemic carboplatin/vincristine/etoposide as a chemotherapy regimen used in retinoblastoma.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Interventional radiologists pass a micro-catheter through the femoral artery up to the orifice of the ophthalmic artery of the eye with retinoblastoma, and chemotherapy (single drug or combination; melphalan, topotecan, carboplatin) is infused in a pulsatile fashion over 30 minutes."
explanation: >-
Describes intra-arterial delivery of melphalan (via a micro-catheter to
the ophthalmic artery) for localized chemotherapy effect.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "primary treatments for intraocular disease include enucleation, intravenous chemotherapy (IVC) with focal therapy (laser therapy, cryotherapy), intra-arterial chemotherapy (IAC) with focal therapy, and focal therapy alone when tumours are small at diagnosis."
explanation: Lists intravenous and intra-arterial chemotherapy, combined with focal consolidation, among the standard primary treatments for intraocular retinoblastoma.
- name: Enucleation
description: >-
Surgical removal of the eye is indicated for advanced intraocular disease,
particularly when vision cannot be preserved. Provides excellent local control
and prevents extraocular spread.
treatment_term:
preferred_term: Enucleation
term:
id: NCIT:C48601
label: Enucleation
evidence:
- reference: PMID:41567907
reference_title: "Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Enucleation remains a definitive treatment option for children with unilateral intraocular retinoblastoma"
explanation: Confirms enucleation as a definitive surgical treatment for intraocular retinoblastoma.
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Enucleation is a first-line therapy for the majority of eyes with retinoblastoma globally; it is the fastest and least costly treatment"
explanation: Establishes enucleation as a first-line treatment for advanced intraocular retinoblastoma globally.
- name: External Beam Radiation
description: >-
Historically used for retinoblastoma but now avoided when possible due to
significantly increased risk of secondary malignancies in RB1 germline
mutation carriers, particularly osteosarcoma in the radiation field.
therapeutic_modality: RADIOTHERAPY
treatment_term:
preferred_term: radiation therapy
term:
id: NCIT:C15313
label: Radiation Therapy
evidence:
- reference: PMID:27189421
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "External beam radiotherapy (EBRT) is no longer recommended for first line therapy for primary intraocular retinoblastoma, since radiation, especially in the first year of life, imposes a high risk of secondary cancers when the patient carries an RB1 mutation."
explanation: Explains why EBRT is now avoided when possible, supporting the description's secondary-malignancy-risk rationale.
- name: Surveillance Eye Examinations in Germline RB1 Carriers
description: >-
Individuals with an RB1 germline pathogenic variant undergo a tapering
schedule of eye examinations (under anesthesia in young children) to
detect new tumor foci as early as possible.
action_category: MONITORING
treatment_term:
preferred_term: eye examination
term:
id: NCIT:C38060
label: Eye Examination
evidence:
- reference: PMID:20301625
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Individuals with an RB1 germline pathogenic variant (H1) should have eye examinations (under anesthesia in young children) every three to four weeks until age six months, every two months until age three years, every three to six months until age seven years, annually until age ten years, and then every two years in order to identify a retinoblastoma as early as possible."
explanation: >-
GeneReviews specifies the surveillance schedule for germline RB1
carriers, tapering examination frequency as the risk of new tumor foci
declines with age.
- name: Avoidance of Radiation and DNA-Damaging Agents in Germline Carriers
description: >-
Beyond avoiding external beam radiotherapy specifically, individuals with
heritable (germline RB1) retinoblastoma are counseled to minimize other
ionizing radiation exposure (x-rays, CT scans) and other DNA-damaging
agents such as tobacco and UV light, to reduce lifetime risk of secondary
malignancy.
action_category: COUNSELING_INFORMATIONAL
treatment_term:
preferred_term: avoidance of radiation and DNA-damaging agents
evidence:
- reference: PMID:20301625
reference_title: "Retinoblastoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "If possible, radiation (including x-rays, CT scans, and external beam radiation) and DNA damaging agents (tobacco, UV light) should be avoided in individuals with heritable retinoblastoma (H1) to minimize the lifetime risk of developing subsequent malignant neoplasms."
explanation: >-
GeneReviews recommends minimizing ionizing-radiation exposure and other
DNA-damaging agents in germline RB1 carriers beyond avoiding EBRT
specifically, to reduce secondary-malignancy risk.
disease_term:
preferred_term: retinoblastoma
term:
id: MONDO:0008380
label: retinoblastoma
classifications:
icdo_morphology:
classification_value: Embryonal Neoplasm
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
nih_research_priority:
- classification_value: NIH_HT_42_rare_cancers_across_cancer_control_continuum
notes: Rare pediatric intraocular malignancy (biallelic RB1, two-hit) — flagship exemplar for NIH Highlighted Topic 42 (rare cancers across the cancer control continuum).
- classification_value: NIH_HT_68_childhood_adolescent_young_adult_aya_cancer
notes: Canonical childhood cancer (biallelic RB1 loss, the two-hit paradigm) — flagship exemplar for NIH Highlighted Topic 68 (childhood and adolescent & young adult cancer research).
datasets:
- accession: ega:EGAS00001000346
title: Genetic landscape of pediatric Retinoblastoma
description: Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1 were inactivated in the tumor samples. 3 of the patients had sporadic retinoblastoma and one patient had inherited retinoblastoma. Overall, there were few single nucleotide changes in coding regions of the genome and some of the tumors had few chromosomal lesions.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: WGS
publication: PMID:22237022
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Retinoblastoma"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000598
title: RB1 Gene Inactivation by Chromothripsis in Human Retinoblastoma
description: Retinoblastoma is a rare childhood cancer of the developing retina. Most retinoblastomas initiate with biallelic inactivation of the RB1 gene through diverse mechanisms including point mutations, nucleotide insertions, deletions, loss of heterozygosity and promoter hypermethylation. Recently, a novel mechanism of retinoblastoma initiation was proposed. Gallie and colleagues discovered that a small proportion of retinoblastomas lack RB1 mutations and had MYCN amplification [1]. In this study, we identified recurrent chromosomal, regional and focal genomic lesions in 94 primary retinoblastomas with their matched normal DNA using SNP 6.0 chips.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Retinoblastoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001001657
title: Exome sequencing of retinoblastoma tumors
description: Retinoblastoma is the most common intraocular cancer of infancy and childhood, with an incidence of one case per 15,000 - 20,000 live births. Patients in developed countries have a good prognosis. However, in most cases, enucleation of the affected eye is required. In low- and middle-income countries, retinoblastoma is frequently lethal. A loss of function of both alleles of the RB1 gene is an early event in the development of retinoblastoma. However, other genes are also likely to be involved in the development of this cancer.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: WES
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Retinoblastoma"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: dbgap:phs000352
title: Sequencing of Retinoblastoma
description: Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1 were inactivated in the tumor samples. 3 of the patients had sporadic retinoblastoma and one patient had inherited retinoblastoma.
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Retinoblastoma"). Retrieved 2026-08-02.
references:
- reference: PMID:20301625
title: "Retinoblastoma."
tags:
- GeneReviews
findings: []
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Disease Pathophysiology Research Report
Target Disease - Disease Name: Retinoblastoma - MONDO ID: MONDO_0008380 (retinoblastoma); related: MONDO_0018160 (hereditary retinoblastoma), MONDO_0003073 (trilateral retinoblastoma) (OpenTargets metadata) (markovic2023geneticsinophthalmology pages 1-2) - Category: Pediatric intraocular malignant embryonal tumor of the retina
1) Core Pathophysiology - Initiation: Most retinoblastomas are initiated by biallelic inactivation of RB1 (Knudson’s two-hit). Patient-derived hiPSC retinal organoids with compound heterozygous RB1 mutations developed retinoblastoma-like tumors in vitro, providing direct experimental validation of the two-hit model (PNAS Nexus, 2022; URL: https://doi.org/10.1093/pnasnexus/pgac162; Aug 2022) (li2022secondhitimpels pages 12-13). A minority of tumors represent a MYCN-driven subgroup (some RB1-proficient), with MYCN activity promoting dedifferentiation and aggressive biology (Communications Biology, 2024; URL: https://doi.org/10.1038/s42003-024-06596-6; Jul 2024) (ryl2024amycndrivendedifferentiation pages 1-2). - Cell-of-origin: Multiple lines of evidence implicate maturing cone photoreceptor precursors as the principal cell-of-origin in RB1-mutant disease; RB1 loss in ARR3+ cone precursors induces proliferation and tumor formation. MYCN-initiated RB arises from more immature cone precursors with lineage deconstraint (PNAS, 2022; URL: https://doi.org/10.1073/pnas.2200721119; Jul 2022). Spatial transcriptomics of human tumors confirms cone-precursor dominance among malignant populations (bioRxiv, 2024; URL: https://doi.org/10.1101/2024.02.05.578886; Feb 2024) (singh2022animmaturededifferentiated pages 10-10, wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5, li2022secondhitimpels pages 12-13). - Dysregulated pathways: RB1/pRB–E2F cell-cycle checkpoint failure is central; downstream cooperation includes p53 pathway suppression through cone-programmed MDM2/MDM4, MYCN activation programs, and context-specific signaling (e.g., PI3K–AKT–mTOR; WNT/Notch/Hedgehog noted in RB literature) (IJMS, 2024; URL: https://doi.org/10.3390/ijms25136910; Jun 2024) (lisek2024histonedeacetylasesin pages 1-2, chavez2023pluripotentstemcellderived pages 56-60, ryl2024amycndrivendedifferentiation pages 1-2). - Epigenetic dysregulation: DNA methylation patterns and enhancer-state changes define molecular subtypes; histone deacetylase activity is intertwined with pRB function and is dysregulated in RB (Communications Biology, 2024; IJMS, 2024) (ryl2024amycndrivendedifferentiation pages 1-2, lisek2024histonedeacetylasesin pages 1-2). Early RB1-deficient tumors can show differentiated histology with few genomic aberrations, followed by dedifferentiation and acquisition of non-cone features, consistent with progressive epigenetic remodeling (2023 organoid/model review) (chavez2023pluripotentstemcellderived pages 56-60). - Microenvironment and hypoxia: Spatial profiling and prior single-cell analyses show tumor-associated macrophages (TAMs), glial cells, and cancer-associated fibroblasts. Hypoxia is relevant to metabolic and survival dependencies; RB1 loss creates a dependency on the nuclear receptor ESRRG, particularly pronounced in hypoxic tumor zones (Science Advances, 2022; URL: https://doi.org/10.1126/sciadv.abm8466; Aug 2022; bioRxiv spatial study 2024) (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5, chavez2023pluripotentstemcellderived pages 56-60). - Metabolism: RB exhibits glycolytic reprogramming; ALDOA (fructose-bisphosphate aldolase A) has been implicated as a modulator of tumorigenesis and tumor–macrophage interactions in RB at single-cell resolution (iScience, 2024; URL: https://doi.org/10.1016/j.isci.2024.110725; Sep 2024; 2023 review) (chavez2023pluripotentstemcellderived pages 56-60).
2) Key Molecular Players, Cell Types, Anatomy, and Chemicals | Entity | Ontology ID | Type | Mechanistic role in RB pathophysiology (1–2 sentences) | Key supporting sources | |---|---|---|---|---| | RB1 | HGNC:9884 | Gene/Protein | Tumor suppressor whose biallelic inactivation (Knudson two‑hit) initiates most retinoblastomas by disabling pRB control of E2F, chromatin remodeling, differentiation and genome stability. | (markovic2023geneticsinophthalmology pages 1-2, li2022secondhitimpels pages 12-13, chavez2023pluripotentstemcellderived pages 56-60) | | MYCN | HGNC:7553 | Gene/Oncogene | Oncogenic amplification drives a distinct RB1‑proficient aggressive subgroup by promoting dedifferentiation, protein synthesis and proliferation programs. | (ryl2024amycndrivendedifferentiation pages 1-2, singh2022animmaturededifferentiated pages 10-10, chavez2023pluripotentstemcellderived pages 56-60) | | MDM2 | HGNC:6973 | Gene/Protein | E3 ligase and p53 inhibitor that is highly expressed in cone‑precursor circuitry, promoting proliferation and survival (supports MYCN translation and blunts p53 responses). | (chavez2023pluripotentstemcellderived pages 56-60, singh2022animmaturededifferentiated pages 10-10, wang2024spatialtranscriptomicprofiling pages 5-8) | | MDM4 | HGNC:6975 | Gene/Protein | Negative regulator of p53 that cooperates with MDM2/p53 axis dysregulation in RB biology, contributing to impaired apoptosis in tumor cells. | (markovic2023geneticsinophthalmology pages 1-2, lisek2024histonedeacetylasesin pages 1-2, chavez2023pluripotentstemcellderived pages 56-60) | | ESRRG | HGNC:3473 | Gene/Protein | Nuclear receptor identified as a dependency after RB1 loss; ESRRG supports retinogenesis/oxygen metabolism programs and its inhibition causes RB cell death, especially in hypoxia. | (chavez2023pluripotentstemcellderived pages 56-60, markovic2023geneticsinophthalmology pages 1-2) | | E2F transcription factors | GO:0001078 | Pathway/Process (TF family) | E2F family are direct transcriptional targets restrained by pRB; when pRB is lost or E2F is overexpressed, E2F drives G1→S genes and uncontrolled proliferation. | (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2, chavez2023pluripotentstemcellderived pages 56-60) | | PI3K/AKT/mTOR signaling | GO:0014065, GO:0035556 | Pathway/Process | Growth‑ and survival‑promoting signaling cascade implicated in retinoblastoma cell survival and resistance mechanisms downstream of oncogenic drivers. | (lisek2024histonedeacetylasesin pages 1-2, wang2024spatialtranscriptomicprofiling pages 5-8) | | WNT signaling | GO:0016055 | Pathway/Process | Developmental pathway involved in retinal development and reported as dysregulated in RB, contributing to proliferation/differentiation imbalance. | (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2) | | Notch signaling | GO:0007219 | Pathway/Process | Developmental signaling that can influence retinal cell fate decisions and has been implicated in RB‑related differentiation/proliferation changes. | (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2) | | Hedgehog signaling | GO:0007224 | Pathway/Process | Developmental morphogen pathway with potential roles in retinal progenitor behavior and tumor biology in RB contexts. | (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2) | | DNA methylation | GO:0006306 | Process (Epigenetic) | Altered CpG methylation and enhancer methylation distinguish RB subtypes and modulate photoreceptor gene programs and immune‑related gene expression. | (ryl2024amycndrivendedifferentiation pages 1-2, wang2024spatialtranscriptomicprofiling pages 5-8, chavez2023pluripotentstemcellderived pages 56-60) | | Histone deacetylase activity / HDACs | GO:0004407 | Molecular function / Epigenetic regulators | HDACs interact with pRB and modulate chromatin states; dysregulated HDAC activity contributes to aberrant transcription, cell‑cycle control and survival in RB. | (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2) | | Cone photoreceptor precursor | CL:0011116 (or nearest) | Cell type | Principal cell‑of‑origin: maturing cone precursors (ARR3+/cone markers) are susceptible to RB1 loss and/or MYCN perturbation and give rise to cone‑like malignant cells. | (li2022secondhitimpels pages 12-13, singh2022animmaturededifferentiated pages 10-10, chavez2023pluripotentstemcellderived pages 56-60, wang2024spatialtranscriptomicprofiling pages 5-8) | | Retina | UBERON:0000966 | Anatomy | Tissue of origin where RB1 inactivation or MYCN activation in developing retinal cells (cone precursors) initiates tumorigenesis. | (markovic2023geneticsinophthalmology pages 1-2, li2022secondhitimpels pages 12-13) | | Tumor‑associated macrophage (TAM) | CL:0000863 | Cell type (TME) | TAMs are abundant in RB microenvironment and can create immunosuppressive niches, modulating invasion and therapeutic response. | (wang2024spatialtranscriptomicprofiling pages 5-8, chavez2023pluripotentstemcellderived pages 56-60, wang2024spatialtranscriptomicprofiling pages 1-5) | | Cancer‑associated fibroblast (CAF) | CL:0002620 | Cell type (TME) | Minor stromal component in RB spatial maps that may support tumor architecture, signaling and extracellular matrix remodeling. | (wang2024spatialtranscriptomicprofiling pages 5-8) | | ALDOA | HGNC:414 | Gene/Protein (metabolic enzyme) | Glycolytic enzyme linked to altered energy metabolism in RB; targeting ALDOA modulates tumorigenesis and tumor‑macrophage interactions. | (chavez2023pluripotentstemcellderived pages 56-60, wang2024spatialtranscriptomicprofiling pages 5-8) | | Glycolytic process | GO:0006096 | Process / Metabolism | Metabolic reprogramming (enhanced glycolysis) supports proliferative/risky RB phenotypes and is associated with MYCN activity and energetic demands. | (chavez2023pluripotentstemcellderived pages 56-60, wang2024spatialtranscriptomicprofiling pages 5-8) |
Table: Table summarizing principal genes, pathways, cell types and anatomical terms implicated in retinoblastoma pathophysiology, with ontology identifiers and supporting evidence (pqac IDs). This provides an at‑a‑glance annotation useful for knowledge‑base curation and mechanistic mapping.
Additional notes and URLs: - RB1 two-hit and pleiotropic pRB functions (Human Genomics, 2023; URL: https://doi.org/10.1186/s40246-023-00529-w; Sep 2023) (markovic2023geneticsinophthalmology pages 1-2). - MYCN-driven RB subgroup and methylation-defined clusters (Communications Biology, 2024; URL above) (ryl2024amycndrivendedifferentiation pages 1-2). - ESRRG dependency after RB1 loss (Science Advances, 2022; URL above) (chavez2023pluripotentstemcellderived pages 56-60). - Spatial heterogeneity and trajectories (bioRxiv, 2024; URL above) (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5). - Organoid validation of the two-hit model (PNAS Nexus, 2022; URL above) (li2022secondhitimpels pages 12-13).
3) Biological Processes (GO) Disrupted - Cell cycle G1/S transition via E2F de-repression (GO:0000082; GO:0051726), DNA replication (GO:0006260), mitotic cell cycle (GO:0000278) (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2). - Regulation of apoptosis and p53 signaling (GO:0043065; GO:0072331), influenced by MDM2/MDM4 elevation in cone circuitry (chavez2023pluripotentstemcellderived pages 56-60, singh2022animmaturededifferentiated pages 10-10). - Photoreceptor differentiation programs and cone development pathways are subverted (GO:0001754, GO:0007601) as cone precursors become proliferative tumor cells (li2022secondhitimpels pages 12-13, singh2022animmaturededifferentiated pages 10-10, wang2024spatialtranscriptomicprofiling pages 5-8). - Epigenetic regulation: DNA methylation (GO:0006306), histone deacetylation (GO:0016575), chromatin remodeling (GO:0006338) (ryl2024amycndrivendedifferentiation pages 1-2, lisek2024histonedeacetylasesin pages 1-2). - Metabolic reprogramming: glycolytic process (GO:0006096) (chavez2023pluripotentstemcellderived pages 56-60). - Pathway dysregulation: PI3K/AKT (GO:0014065), WNT (GO:0016055), Notch (GO:0007219), Hedgehog (GO:0007224) in RB contexts (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2).
4) Cellular Components (GO/Anatomy) - Nucleus (GO:0005634) and chromatin (GO:0000785): pRB–E2F control and epigenetic modifiers including HDACs (lisek2024histonedeacetylasesin pages 1-2, markovic2023geneticsinophthalmology pages 1-2). - Mitochondrion and metabolic complexes (GO:0005739): ESRRG-regulated oxidative programs intersecting with hypoxia responses (chavez2023pluripotentstemcellderived pages 56-60). - Retina (UBERON:0000966) with dominant malignant cone-precursor compartments; tumor niches containing TAMs and CAFs (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5).
5) Disease Progression - Heritable RB (germline RB1 mutation) typically presents earlier and often bilaterally; progression often follows an indolent retinoma stage (genomic instability, retinocytoma/retinoma) to invasive RB upon acquiring additional alterations and epigenetic dedifferentiation (PNAS, 2022; Human Genomics, 2023) (singh2022animmaturededifferentiated pages 10-10, markovic2023geneticsinophthalmology pages 1-2). - Sporadic RB commonly involves somatic biallelic RB1 loss; a subset are MYCN-driven (some RB1-proficient) that rapidly transform from immature cone precursors and are more aggressive with dedifferentiated/stemness features (PNAS, 2022; Communications Biology, 2024) (singh2022animmaturededifferentiated pages 10-10, ryl2024amycndrivendedifferentiation pages 1-2). - Spatial and single-cell pseudotime/velocity analyses show trajectories from cone-precursor-like states to highly proliferative/malignant clusters with increasing CNVs and cell-cycle gene expression (bioRxiv, 2024) (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5).
6) Phenotypic Manifestations (HP terms and links to mechanisms) - Leukocoria (HP:0001083) and strabismus (HP:0000486) as presenting signs are downstream of intraocular tumor mass arising from cone-precursor transformation (linked to RB1 loss/MYCN activity) (markovic2023geneticsinophthalmology pages 1-2). - Bilateral disease (HP:0005247) in heritable cases due to germline RB1 mutation and independent second hits in both eyes (markovic2023geneticsinophthalmology pages 1-2, li2022secondhitimpels pages 12-13). - Histologic heterogeneity including differentiated rosettes (Flexner–Wintersteiner) in early/differentiated tumors and dedifferentiated patterns in aggressive subtype 2 (ryl2024amycndrivendedifferentiation pages 1-2, markovic2023geneticsinophthalmology pages 1-2).
7) Current Applications and Implementations - Organoid models: Human retinal organoids from patient-derived hiPSCs with engineered second-hit RB1 mutations recapitulate tumorigenesis, enabling mechanistic and drug response studies (PNAS Nexus, 2022; URL above) (li2022secondhitimpels pages 12-13). - Spatial/single-cell profiling: Spatial transcriptomics has provided the first spatial gene atlas for RB, mapping subclonal architecture and TME interactions to inform targeted therapy strategies (bioRxiv, 2024; URL above) (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5). - Emerging dependencies/targets: ESRRG inhibitors as a potential therapeutic strategy in RB1-deficient RB, particularly under hypoxia (Science Advances, 2022; URL above) (chavez2023pluripotentstemcellderived pages 56-60). MYCN-targeted approaches could restore photoreceptor differentiation programs in MYCN-driven RB models (Communications Biology, 2024; URL above) (ryl2024amycndrivendedifferentiation pages 1-2). Epigenetic modulators (HDAC-focused strategies) are being explored preclinically (IJMS, 2024; URL above) (lisek2024histonedeacetylasesin pages 1-2). Metabolic targeting of ALDOA/glycolysis is emerging (iScience, 2024; URL above) (chavez2023pluripotentstemcellderived pages 56-60). - Diagnostics: Cell-free tumor DNA from the anterior segment of the eye can be used for RB diagnostics/prognostics (Human Genomics, 2023; URL above) (markovic2023geneticsinophthalmology pages 1-2).
8) Expert Opinions, Statistics, and Data (2023–2024 emphasis) - Global burden: “8,000 new cases … each year worldwide,” highlighting RB as the most frequent pediatric intraocular malignancy (Human Genomics, 2023; Sep 2023) (markovic2023geneticsinophthalmology pages 1-2). - Molecular subtypes: Two major subtypes—Subtype 1 (differentiated photoreceptor signature; fewer additional alterations) and Subtype 2 (dedifferentiated cone states with neuronal/ganglion markers; frequent CNAs and MYCN activation)—inform risk and therapeutic strategies (Nature Communications synthesis cited within 2023 review; and Communications Biology, 2024) (markovic2023geneticsinophthalmology pages 1-2, ryl2024amycndrivendedifferentiation pages 1-2). - Spatial heterogeneity: Ten spatially distinct tumor subpopulations with varying proliferative capacities; dominant cone-precursor lineage with glial and CAF contributions (bioRxiv, 2024) (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5).
9) Evidence Items (select primary literature with PMIDs/DOIs/URLs) - Li et al., PNAS Nexus, 2022 (two-hit validation in organoids). DOI: 10.1093/pnasnexus/pgac162; URL: https://doi.org/10.1093/pnasnexus/pgac162; Publication date: Aug 2022 (li2022secondhitimpels pages 12-13). - Singh et al., PNAS, 2022 (MYCN-initiated RB cell-of-origin in immature cones). DOI: 10.1073/pnas.2200721119; URL: https://doi.org/10.1073/pnas.2200721119; Publication date: Jul 2022 (singh2022animmaturededifferentiated pages 10-10). - Ryl et al., Communications Biology, 2024 (MYCN-driven subgroup and methylation-defined clusters). DOI: 10.1038/s42003-024-06596-6; URL: https://doi.org/10.1038/s42003-024-06596-6; Publication date: Jul 2024 (ryl2024amycndrivendedifferentiation pages 1-2). - Field et al., Science Advances, 2022 (ESRRG dependency after RB1 loss; hypoxia). DOI: 10.1126/sciadv.abm8466; URL: https://doi.org/10.1126/sciadv.abm8466; Publication date: Aug 2022 (chavez2023pluripotentstemcellderived pages 56-60). - Wang et al., bioRxiv, 2024 (spatial transcriptomics in human RB). DOI: 10.1101/2024.02.05.578886; URL: https://doi.org/10.1101/2024.02.05.578886; Publication date: Feb 2024 (wang2024spatialtranscriptomicprofiling pages 5-8, wang2024spatialtranscriptomicprofiling pages 1-5). - Lisek et al., IJMS, 2024 (HDACs in RB). DOI: 10.3390/ijms25136910; URL: https://doi.org/10.3390/ijms25136910; Publication date: Jun 2024 (lisek2024histonedeacetylasesin pages 1-2). - Marković et al., Human Genomics, 2023 (Genetics and subtypes, epidemiology). DOI: 10.1186/s40246-023-00529-w; URL: https://doi.org/10.1186/s40246-023-00529-w; Publication date: Sep 2023 (markovic2023geneticsinophthalmology pages 1-2).
Ontology Annotations (examples) - HGNC: RB1 (HGNC:9884), MYCN (HGNC:7553), MDM2 (HGNC:6973), MDM4 (HGNC:6975), ESRRG (HGNC:3473), ALDOA (HGNC:414) (markovic2023geneticsinophthalmology pages 1-2, ryl2024amycndrivendedifferentiation pages 1-2, chavez2023pluripotentstemcellderived pages 56-60). - GO Processes: cell cycle (GO:0007049), DNA methylation (GO:0006306), histone deacetylation (GO:0016575), glycolytic process (GO:0006096) (lisek2024histonedeacetylasesin pages 1-2, ryl2024amycndrivendedifferentiation pages 1-2, chavez2023pluripotentstemcellderived pages 56-60). - CL: Cone photoreceptor precursor (CL:0011116); TAM (CL:0000863); CAF (CL:0002620) (li2022secondhitimpels pages 12-13, wang2024spatialtranscriptomicprofiling pages 5-8). - UBERON: Retina (UBERON:0000966) (markovic2023geneticsinophthalmology pages 1-2). - CHEBI: While specific chemotherapeutic entities are beyond the mechanistic scope here, metabolic substrates (e.g., D-glucose, CHEBI:17234) are relevant to glycolysis; metabolic targeting has focused on enzymes such as ALDOA (chavez2023pluripotentstemcellderived pages 56-60).
Expert synthesis - The central unifying mechanism is RB1 loss disabling pRB’s control of E2F and chromatin, unleashing a cone-intrinsic proliferation circuitry augmented by MDM2/MDM4 and MYCN programs. Tumor evolution proceeds along cone-precursor lineages toward proliferative, CNV-rich states with progressive epigenetic dedifferentiation, while microenvironmental hypoxia and stromal cues (TAMs/CAFs) shape survival dependencies such as ESRRG. MYCN-driven, RB1-proficient disease reflects a distinct developmental susceptibility of immature cone states, with therapeutic implications for MYCN pathway inhibition and differentiation rescue (markovic2023geneticsinophthalmology pages 1-2, ryl2024amycndrivendedifferentiation pages 1-2, singh2022animmaturededifferentiated pages 10-10, wang2024spatialtranscriptomicprofiling pages 5-8, chavez2023pluripotentstemcellderived pages 56-60, lisek2024histonedeacetylasesin pages 1-2).
References
(markovic2023geneticsinophthalmology pages 1-2): Leon Marković, Anja Bukovac, Ana Maria Varošanec, Nika Šlaus, and Nives Pećina-Šlaus. Genetics in ophthalmology: molecular blueprints of retinoblastoma. Human Genomics, Sep 2023. URL: https://doi.org/10.1186/s40246-023-00529-w, doi:10.1186/s40246-023-00529-w. This article has 41 citations and is from a peer-reviewed journal.
(li2022secondhitimpels pages 12-13): Yan-Ping Li, Ya-Ting Wang, Wen Wang, Xiao Zhang, Ren-Juan Shen, Kangxin Jin, Li-Wen Jin, and Zi-Bing Jin. Second hit impels oncogenesis of retinoblastoma in patient-induced pluripotent stem cell-derived retinal organoids: direct evidence for knudson's theory. PNAS Nexus, Aug 2022. URL: https://doi.org/10.1093/pnasnexus/pgac162, doi:10.1093/pnasnexus/pgac162. This article has 27 citations and is from a peer-reviewed journal.
(ryl2024amycndrivendedifferentiation pages 1-2): Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T. W. Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hanenberg, Sven Rahmann, Dietmar R. Lohmann, Alexander Schramm, and Petra Ketteler. A mycn-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications Biology, Jul 2024. URL: https://doi.org/10.1038/s42003-024-06596-6, doi:10.1038/s42003-024-06596-6. This article has 10 citations and is from a peer-reviewed journal.
(singh2022animmaturededifferentiated pages 10-10): Hardeep P. Singh, Dominic W. H. Shayler, G. Esteban Fernandez, Matthew E. Thornton, Cheryl Mae Craft, Brendan H. Grubbs, and David Cobrinik. An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of n-myc–initiated retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, Jul 2022. URL: https://doi.org/10.1073/pnas.2200721119, doi:10.1073/pnas.2200721119. This article has 29 citations and is from a highest quality peer-reviewed journal.
(wang2024spatialtranscriptomicprofiling pages 5-8): Luozixian Wang, Sandy Hung, Daniel Urrutia-Cabrera, Roy C. K. Kong, Sandra Staffieri, Louise E. Ludlow, Xianzhong Lau, Peng-Yuan Wang, Alex W. Hewitt, and Raymond C.B. Wong. Spatial transcriptomic profiling of human retinoblastoma. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.05.578886, doi:10.1101/2024.02.05.578886. This article has 0 citations and is from a poor quality or predatory journal.
(wang2024spatialtranscriptomicprofiling pages 1-5): Luozixian Wang, Sandy Hung, Daniel Urrutia-Cabrera, Roy C. K. Kong, Sandra Staffieri, Louise E. Ludlow, Xianzhong Lau, Peng-Yuan Wang, Alex W. Hewitt, and Raymond C.B. Wong. Spatial transcriptomic profiling of human retinoblastoma. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.05.578886, doi:10.1101/2024.02.05.578886. This article has 0 citations and is from a poor quality or predatory journal.
(lisek2024histonedeacetylasesin pages 1-2): Malwina Lisek, Julia Tomczak, Julia Swiatek, Aleksandra Kaluza, and Tomasz Boczek. Histone deacetylases in retinoblastoma. International Journal of Molecular Sciences, 25:6910, Jun 2024. URL: https://doi.org/10.3390/ijms25136910, doi:10.3390/ijms25136910. This article has 3 citations and is from a poor quality or predatory journal.
(chavez2023pluripotentstemcellderived pages 56-60): R Cerna Chavez. Pluripotent stem cell-derived retinal organoids and retinal pigment epithelium as a model system for screening chemotherapeutic agents in retinoblastoma. Unknown journal, 2023.